Today: 20 March 2026
Subscribe
Browse Category

CSE:NOVO.B 17 January 2026 - 20 March 2026

Novo Nordisk Stock Price Slips Even After FDA Clears High-Dose Wegovy

Novo Nordisk Stock Price Slips Even After FDA Clears High-Dose Wegovy

Novo Nordisk shares fell 1.5% in Copenhagen Thursday despite FDA approval of a higher-dose Wegovy shot. Shares stayed down as Eli Lilly released new obesity drug data and Reuters reported India’s semaglutide patent expiry will allow cheaper generics. Novo expects to launch the 7.2-mg Wegovy in the U.S. in April. Over 40 Indian drugmakers are preparing generic versions as prices are set to drop.
20 March 2026
···
Novo Nordisk Class B stock price: Wegovy pill scripts hit 26,000 as earnings week approaches

Novo Nordisk Class B stock price: Wegovy pill scripts hit 26,000 as earnings week approaches

Novo Nordisk Class B shares closed down 0.23% at 369.55 Danish kroner Friday, capping a 7.9% slide over five sessions. U.S. prescriptions for oral Wegovy reached 26,109 in the week ending Jan. 23, after 3,071 in the first four days post-launch. The company faces rising competition in China and awaits EU approval for its MASH drug. Quarterly results and 2026 outlook are due Feb. 4.
31 January 2026
···
Novo Nordisk stock drops in Copenhagen as Wegovy pill demand gets its first real test

Novo Nordisk stock drops in Copenhagen as Wegovy pill demand gets its first real test

Novo Nordisk B shares fell 2.8% Monday in Copenhagen, closing at 378.15 crowns as investors reacted to early U.S. prescription data for the new oral form of Wegovy. Around 4.7 million shares traded. U.S. prescriptions for oral Wegovy reached nearly 3,100 for the week ending Jan. 9, while overall Wegovy prescriptions dropped 11%. Full-year results are due Feb. 4.
19 January 2026
··
Novo Nordisk stock rallies: Wegovy pill scripts and UK higher-dose nod put NOVO-B back in play

Novo Nordisk stock rallies: Wegovy pill scripts and UK higher-dose nod put NOVO-B back in play

Novo Nordisk A/S Class B shares surged 6.5% to 388.9 Danish crowns Friday in Copenhagen after early U.S. prescription data for the new Wegovy pill surfaced and Britain approved a higher Wegovy dose for certain obesity patients. Trading volume reached 13.9 million shares. IQVIA data showed 3,071 U.S. retail prescriptions for the pill in its first four days, not counting online orders.
17 January 2026
··

Stock Market Today

  • BitFuFu Inc. Reports Q4 Loss, Revenue Misses Estimates Amid Market Underperformance
    March 20, 2026, 9:20 AM EDT. BitFuFu Inc. (FUFU) reported a fourth-quarter loss of $0.20 per share, far missing the expected loss of $0.02 and down from a profit of $0.14 a year ago, marking a negative earnings surprise of 1,233%. Revenue came in at $101.66 million, slightly below estimates by 3.32%, with only one revenue beat in the last four quarters. Shares have declined nearly 15% in 2025, notably underperforming the S&P 500's 3.5% drop. The company carries a Zacks Rank #4 (Sell) due to unfavorable recent earnings estimate revisions. Consensus estimates for the next quarter are $0.04 EPS and $129.76 million revenue. Market watchers will focus on management commentary and industry trends as the Financial - Miscellaneous Services sector ranks in the bottom 38% among 250 industries.
Go toTop